Cambridge Trust Co. Has $14.68 Million Holdings in Agilent Technologies, Inc. (NYSE:A)

Cambridge Trust Co. boosted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 89.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 105,569 shares of the medical research company’s stock after purchasing an additional 49,761 shares during the period. Cambridge Trust Co.’s holdings in Agilent Technologies were worth $14,677,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Money Concepts Capital Corp acquired a new stake in Agilent Technologies during the fourth quarter worth about $26,000. MV Capital Management Inc. grew its stake in Agilent Technologies by 120.7% during the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after buying an additional 105 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Agilent Technologies during the fourth quarter worth about $34,000. OFI Invest Asset Management acquired a new stake in Agilent Technologies during the third quarter worth about $25,000. Finally, Baystate Wealth Management LLC lifted its holdings in shares of Agilent Technologies by 107.3% in the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after acquiring an additional 133 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Barclays increased their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Stifel Nicolaus raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $145.00 to $163.00 in a report on Friday, April 5th. Oppenheimer increased their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. increased their target price on shares of Agilent Technologies from $140.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Finally, UBS Group increased their target price on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $141.29.

Insiders Place Their Bets

In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares in the company, valued at $7,935,235.84. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Rodney Gonsalves sold 4,828 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $149.00, for a total transaction of $719,372.00. Following the sale, the vice president now owns 21,329 shares in the company, valued at approximately $3,178,021. The disclosure for this sale can be found here. Insiders sold a total of 61,610 shares of company stock valued at $9,220,333 over the last quarter.

Agilent Technologies Price Performance

Shares of NYSE A traded down $2.24 during midday trading on Thursday, hitting $132.31. 1,191,383 shares of the company’s stock were exchanged, compared to its average volume of 1,578,407. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $151.58. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. The company has a market cap of $38.77 billion, a price-to-earnings ratio of 31.50, a PEG ratio of 4.14 and a beta of 1.11. The business’s fifty day moving average price is $141.22 and its two-hundred day moving average price is $129.48.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.22 by $0.07. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. Agilent Technologies’s revenue was down 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.37 earnings per share. As a group, research analysts forecast that Agilent Technologies, Inc. will post 5.51 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd will be paid a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.